American Marconi Wireless News - Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

• BUZZ BOMB™ engages three specialized fitness influencers to grow the brand

  • https://www.instagram.com/bobbymaximus/

  • https://www.instagram.com/midwest_kong/

  • https://www.instagram.com/ifbbpro_moose_the_stallion/

• The influencers have hundreds of thousands of followers across social platforms

• BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world

• Sublingual delivery of 50mg of caffeine to the user in less than two minutes

• BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's E-commerce website

ESTERO, FL / ACCESS Newswire / September 17, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced it has launched its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ pre-workout product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed for immediate effect.

Kraig Higginson, Interim Chief Executive Officer of Aspire, commented, "We are thrilled to have three well-respected and accomplished athletes collaborating with us to share the benefits of BUZZ BOMB™ with their followers, which total close to 1 million people. BUZZ BOMB™ represents a truly innovative product in the multi-billion-dollar pre-workout space and we are very excited about the initial launch results and feedback from many well-known fitness instructors, athletes, and influencers along with thousands of fitness enthusiasts and consumers who sampled BUZZ BOMB™ at the two major fitness conventions held in August. By partnering with influencers who already have strong, authentic connections with their highly engaged followers, Aspire aims to increase brand credibility and consumer trust while driving faster sales of our BUZZ BOMB™ pre-workout product."

BUZZ BOMB™ Engages Three Specialized Influencers to Grow the Brand

Bobby Maximus is a UFC fighter, Ju Jitsu Masters World Champion and fitness trainer. He has broken multiple power-endurance world records and is recognized as a leading figure in the fitness world. He starred in the recent feature film "Kill Shot" and is a best-selling Men's Health author and a regular contributor to "Men's Health" magazine. For more about Booby Maximus, please visit https://www.bobbymaximus.com/about-2 of follow him on Instagram at https://www.instagram.com/bobbymaximus/?hl=en

Brandon "MidWest Kong" Copeland (pictured above, third to the right) embodies the strength of a champion and the heart of a hero. A Brazilian Jiu-jitsu Black Belt, Copeland dominated the Mixed Martial Arts scene from 2005 to 2014, showcasing tenacity and skill. Initiating the "I Stopped The Bully" campaign in 2011, he became a beacon against bullying, inspiring youth across schools and detention centers. Copeland excelled in the fitness industry, breaking records like bench pressing 225 pounds 81 consecutive times. A published children's book author, he spreads messages of hope and community. For more about Brandon Copeland, follow him on Instagram at https://www.instagram.com/midwest_kong/

Mustafa Khater aka "The Stallion":

The Stallion is an internationally ranked competitive male body builder. He has consistently placed in the top 5 Mr. World renowned Mr. Olympia international competition, and for 3 consecutive years he has place in the top 3, an honor only a few have ever achieved. He also placed first in the Mr. California body building competition. In addition to body building competition, Mustafa also is a well-known Trainer, and professional fitness coach including online coaching and training. Mustafa has a large following online of nearly 275,000 dedicated students and fans.

Follow Mustafa Khater on Instagram at https://www.instagram.com/ifbbpro_moose_the_stallion/?hl=en

BUZZ BOMB™ Pre-workout Benefits:

• Speed - works nearly immediately (less than 2 minutes) vs. 20-30 minutes

• Convenience - easy to use single-use packets vs. mixing and measuring for beverages

• Energy management - use as needed to precisely manage caffeine intake (50mg increments)

• Single Safe Active Ingredient - well-known benefits and use of caffeine

  • A clean manageable Energy Boost

• Low manufacturing & packaging costs - competitive pricing with high margin potential

Aspire's BUZZ BOMB™ - Delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma delivers supplements to the body rapidly and precisely.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

L.Harper--AMWN